Workflow
BSBE(300406)
icon
Search documents
6月27日晚间重要公告一览
Xi Niu Cai Jing· 2025-06-27 10:35
Group 1 - Hengbang Co., Ltd. plans to establish a joint venture with Huasheng Development with a registered capital of 10 million yuan, where Hengbang will contribute 8 million yuan (80%) and Huasheng will contribute 2 million yuan (20%) [1] - Hunan Gold's subsidiary Anhua Zhazi Creek Smelting Plant will undergo temporary maintenance starting from the end of June 2025, expected to last no more than 30 days [2] - Defu Technology's subsidiary signed supply agreements for lithium battery copper foil products with two leading global companies, with contract durations of 3 years and 5 years respectively [3] Group 2 - Binjiang Group won the rights to two residential land parcels for a total price of 4.368 billion yuan [5] - Zhong'an Technology announced the resignation of its executive vice president and board secretary due to personal reasons [7] - Changqing Technology's project for special polymer materials and electronic materials has officially commenced production, adding a capacity of 120,500 tons per year [10] Group 3 - Gansu Energy received approval from the China Securities Regulatory Commission to publicly issue bonds totaling up to 2 billion yuan [10] - Shuoshi Biology obtained a medical device registration certificate for an in vitro diagnostic reagent, valid until June 2030 [12] - Yawen Co., Ltd. plans to issue shares to specific investors, with the application accepted by the Shenzhen Stock Exchange [13] Group 4 - Guoyao Modern's subsidiary received approval for the listing of a raw material drug, which is a selective anticholinergic agent [16] - Inner Mongolia First Machinery's subsidiary signed a railway freight car procurement contract worth 130 million yuan [18] - Xining Special Steel plans to raise up to 1 billion yuan through a private placement to its controlling shareholder [39] Group 5 - Huadong Medicine's subsidiary received approval for a clinical trial of a new injectable drug targeting advanced solid tumors [29] - Warner Pharmaceutical's compound potassium hydrogen phosphate injection passed the consistency evaluation for generic drugs [30] - North Special Technology plans to raise up to 300 million yuan through a private placement for a production base project in Thailand [30] Group 6 - Xiangyang Technology is the first candidate for a 533 million yuan Airbus project [45] - Haishun New Materials intends to acquire 100% of Guangdong Zhengyi Packaging [46] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.73% due to personal financial needs [47]
九强生物(300406) - 关于公司获得发明专利证书的公告
2025-06-27 07:40
| 证券代码:300406 | 证券简称:九强生物 | 公告编号:2025-051 | | --- | --- | --- | | 债券代码:123150 | 债券简称:九强转债 | | 北京九强生物技术股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记 载、误导性陈述或者重大遗漏。 | 一、专利基本情况 | | --- | | 序号 | 专利号 | 专利名称 | 专利权人 专利类型 申请日期 | 授权日期 | 证书号 | | --- | --- | --- | --- | --- | --- | | 1 | 7689563 | 检测待检测 样本的前带 | 九强生物 发明 2023.11.21 | 2025.05.29 | N/A | | | | 现象的量化 | | | | | | | 方法和装置 | | | | 注:发明专利权期限为自申请日起二十年。 发明专利摘要: 本发明涉及检测待检测样本的前带现象的量化方法和装置。方法包括:利用 参考样本的实际的抗原浓度和反应曲线的曲率或长度来构建第一定标曲线;根据 待检测样本计算出的反应曲线的曲率或长度来确定 ...
九强生物: 北京九强生物技术股份有限公司相关债券2025年跟踪评级报告
Zheng Quan Zhi Xing· 2025-06-26 16:06
Core Viewpoint - The credit rating agency has maintained a stable credit rating for Beijing Jiukang Biotechnology Co., Ltd., reflecting its strong technical advantages and profitability in the biochemical immunology and pathological diagnosis sectors, while also highlighting potential risks due to increasing competition in the medical consumables industry [3][5][8]. Company Overview - Beijing Jiukang Biotechnology Co., Ltd. focuses on the research, production, and sales of in vitro diagnostic reagents, with a strong presence in biochemical immunology and pathological diagnosis [3][5]. - The company has a credit rating of AA- with a stable outlook, indicating robust financial health and operational stability [3][8]. Financial Performance - The company's total assets reached 56.31 billion, with equity attributable to shareholders at 42.20 billion as of March 2025 [3][4]. - Revenue for 2024 was reported at 16.59 billion, a decrease of 4.75% year-on-year, while net profit was 5.31 billion, reflecting a decline of 32.08% in the first quarter of 2025 [3][7][17]. - The gross profit margin increased by 3.84 percentage points to 78.50% in 2024, driven by higher sales from its subsidiary, Mai Xin Biotechnology [5][17]. Research and Development - The company increased its R&D investment to 1.89 billion in 2024, a growth of 15.73% year-on-year, with R&D expenses accounting for 11.36% of revenue [5][20]. - The number of medical device registration certificates rose to 379 by the end of 2024, with 228 patents held, indicating a strong focus on innovation [5][19]. Market Position and Competition - The company faces increasing competition in the medical consumables sector, which may impact revenue and profit margins if its technological advantages diminish [6][7]. - The in vitro diagnostic market in China is projected to grow, with a market size expected to exceed 1,200 billion by 2024, driven by rising health awareness and aging population [15][16]. Risks and Challenges - The company has significant goodwill from acquisitions, which accounted for 29.70% of total assets as of March 2025, posing a risk of impairment if acquired entities do not perform as expected [7][8]. - There is a reliance on imported raw materials for production, which could lead to supply shortages or price instability [6][23].
九强生物收盘下跌1.59%,滚动市盈率16.13倍,总市值79.89亿元
Sou Hu Cai Jing· 2025-06-26 10:17
Company Overview - Beijing Jiukang Biological Technology Co., Ltd. specializes in the research, production, and sales of biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology diagnostics [1] - The main products include in vitro diagnostic reagents, in vitro testing instruments, instrument leasing, inspection services, and laboratory auxiliary services [1] Financial Performance - As of the first quarter of 2025, the company reported revenue of 320 million yuan, a year-on-year decrease of 18.81% [1] - The net profit for the same period was 83.26 million yuan, down 30.99% year-on-year, with a gross profit margin of 80.84% [1] Market Position - The company's current stock price is 13.58 yuan, with a rolling price-to-earnings (PE) ratio of 16.13 times [1] - The average PE ratio in the medical device industry is 49.45 times, with a median of 35.92 times, placing Jiukang Biological at the 39th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders is 15,231, a decrease of 547 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Recognition - On February 22, 2023, the company was recognized as a "National Enterprise Technology Center" in the 29th batch of newly identified national enterprise technology centers [1]
九强生物(300406) - 北京九强生物技术股份有限公司相关债券2025年跟踪评级报告
2025-06-26 07:40
北京九强生物技术股份有限公司 相关债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【439】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外,本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务,有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则,但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断,不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见,不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效,有效期为被评证券的存续期。同时,本评级机构已对受 评对象的跟踪评级事项做出了明确安排,并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有,未经 ...
九强生物: 中国国际金融股份有限公司关于北京九强生物技术股份有限公司向不特定对象发行可转换公司债券受托管理事务报告(2024年度)
Zheng Quan Zhi Xing· 2025-06-24 16:50
Core Viewpoint - Beijing Strong Biotechnologies, Inc. (referred to as "the Company") has issued convertible bonds to raise funds for its diversified and high-quality in vitro diagnostic testing platform, with a total fundraising amount of RMB 1.139 billion [3][16]. Section 1: Bond Issuance Details - The Company approved the issuance of convertible bonds on September 6, 2021, and received regulatory approval from the China Securities Regulatory Commission on June 6, 2022 [2][3]. - A total of 11.39 million convertible bonds were issued at a face value of RMB 100 each, raising a gross amount of RMB 113.9 million, with a net amount of RMB 112.685 million after deducting issuance costs [3][4]. Section 2: Financial Performance - For the fiscal year 2024, the Company reported a revenue of RMB 165,893.20 million, a decrease of 4.75% compared to RMB 174,162.67 million in 2023 [21]. - The net profit attributable to shareholders increased by 1.70% to RMB 53,263.53 million from RMB 52,374.28 million in the previous year [22]. - The total assets of the Company grew by 7.71% to RMB 557,496.52 million, while the net assets attributable to shareholders increased by 11.11% to RMB 413,837.41 million [22]. Section 3: Use of Proceeds - The net proceeds from the bond issuance will be allocated to various projects, with a total planned investment of RMB 128.9 million [16][18]. - The Company will self-finance any shortfall if the actual net proceeds are less than the planned investment amount [19]. Section 4: Bondholder Rights and Management - The bondholders have rights to interest payments, conversion to shares, and the ability to sell back their bonds under certain conditions [15][12]. - The Company has established a special account for managing the proceeds from the bond issuance, ensuring that funds are used as intended [23]. Section 5: Credit Rating - The Company has maintained a credit rating of AA- with a stable outlook from Zhongjian Pengyuan Credit Rating Co., Ltd. since November 2021 [20][27].
九强生物(300406) - 中国国际金融股份有限公司关于北京九强生物技术股份有限公司向不特定对象发行可转换公司债券受托管理事务报告(2024年度)
2025-06-24 08:40
可转债代码:123150.SZ 可转债简称:九强转债 证券代码:300406.SZ 证券简称:九强生物 北京九强生物技术股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 (2024 年度) 债券受托管理人 二〇二五年六月 重要声明 本报告依据《公司债券发行与交易管理办法》(以下简称"《管理办 法》")、《关于北京九强生物技术股份有限公司向不特定对象发行可转换公 司债券之债券受托管理协议》(以下简称"《受托管理协议》")、《北京九 强生物技术股份有限公司创业板向不特定对象发行可转换公司债券募集说明书》 (以下简称"《募集说明书》")、《北京九强生物技术股份有限公司 2024 年 年度报告》等相关公开信息披露文件、第三方中介机构出具的专业意见等,由 本期债券受托管理人中国国际金融股份有限公司(以下简称"中金公司")编 制。中金公司对本报告中所包含的从上述文件中引述内容和信息未进行独立验 证,也不就该等引述内容和信息的真实性、准确性和完整性做出任何保证或承 担任何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见,投资者应对相 关事宜做出独立判断,而不应将本报告中的任何内容据以作为中金公司所作 ...
九强生物(300406) - 关于公司持股5%以上股东增持公司股份计划的公告
2025-06-23 10:52
| 证券代码:300406 | 证券简称:九强生物 公告编号:2025-049 | | --- | --- | | 债券代码:123150 | 债券简称:九强转债 | 北京九强生物技术股份有限公司 关于公司持股 5%以上股东增持公司股份计划的公告 持股 5%以上的股东中国医药投资有限公司保证向本公司提供的信息内容真 实、准确、完整,没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示: 1、持股 5%以上的股东中国医药投资有限公司(以下简称"增持主体")计 划自 2025 年 6 月 23 日至 2025 年 12 月 22 日,通过集中竞价交易、大宗交易等 法律法规允许的方式增持公司股票,计划增持公司股份金额不少于 3000 万元(含) 人民币(含 2025 年 6 月 23 日已增持部分),增持所需资金为自有资金。 2、本次增持计划可能存在因资本市场情况发生变化或目前尚无法预判的其 他风险因素,导致增持计划的实施无法达到预期的风险。如增持计划实施过程中 出现上述风险情形,公司将及时履行信息披露义务。敬请广大投资者注意投资风 险。 北京九强生物技 ...
九强生物(300406) - 关于持股5%以上股东持股比例变动超过1%的公告
2025-06-23 10:52
持股 5%以上的股东中国医药投资有限公司保证向本公司提供的信息内容真实、准确、 完整,没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 北京九强生物技术股份有限公司(以下简称"公司")于 2024 年 6 月 25 日披露了《关于持股 5%以上股东持股比例变动超过 1%的公告》(公告编号: 2024-047)。2025 年 6 月 23 日收到持股 5%以上股东中国医药投资有限公司 (以下简称"国药投资")的《中国医药投资有限公司关于北京九强生物技术 股份有限公司股份增持情况及拟继续增持股份的函》,至此国药投资于 2024 年 6 月 25 日至 2025 年 6 月 20 日通过深圳证券交易所交易系统以集中竞价方 式增持公司股份合计 594.58 万股,占公司目前有表决权股份比例(扣除公司 回购专用证券账户中的股份数,下同)的 1.02%,增持前占公司目前有表决权 股份比例为 17.02%,增持后占公司目前有表决权股份比例为 18.04%,增持股 份触及 1%整数倍,现将本次权益变动的具体情况公告如下: | 证券代码:300406 | 证券简称:九强生 ...
九强生物(300406) - 创业板向不特定对象发行可转换公司债券2025年付息公告
2025-06-23 09:16
北京九强生物技术股份有限公司 创业板向不特定对象发行可转换公司债券 2025 年付息公告 | 证券代码: | 300406 | 证券简称: | 九强生物 | 公告编号:2025-050 | | --- | --- | --- | --- | --- | | 债券代码: | 123150 | 债券简称: | 九强转债 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 特别提示: 1、"九强转债"(债券代码:123150)将于 2025 年 6 月 30 日按面值支付 第三年利息,每 10 张"九强转债"(面值 1,000.00 元)利息为 10.00 元(含税)。 2、债权登记日:2025 年 6 月 27 日。 3、付息日:2025 年 6 月 30 日。 4、除息日:2025 年 6 月 30 日。 5、"九强转债"票面利率:第一年 0.3%、第二年 0.5%、第三年 1.0%、第 四年 1.5%、第五年 2.3%、第六年 3.0%。 6、"九强转债"本次付息的债权登记日为 2025 年 6 月 27 日,凡在 2025 年 6 月 27 日(含)前买 ...